4921521F21Rik Inhibitors

The chemical class of Akr1cl inhibitors encompasses a diverse range of compounds that can indirectly affect the activity or expression of Akr1cl through modulation of various biological pathways and processes. These inhibitors are not specific to Akr1cl but can impact its function through their influence on related metabolic or signaling pathways.

The NSAIDs flufenamic acid and indomethacin are known to inhibit prostaglandin synthetases and cyclooxygenases, respectively, potentially affecting prostaglandin synthesis where Akr1cl might play a role. Fomepizole and disulfiram target alcohol and aldehyde dehydrogenases, possibly altering the metabolism of substrates that Akr1cl could act upon. The aldose reductase inhibitors epalrestat, sorbinil, and zopolrestat can disrupt the polyol pathway, which may indirectly affect the metabolic context of Akr1cl. Compounds such as oleanolic acid, quercetin, sulforaphane, and resveratrol are known to modulate various metabolic pathways, some of which might intersect with Akr1cl's activity. These effects include modulation of enzyme activity, alteration of oxidative stress responses, and impacts on cellular detoxification processes. Lastly, menadione's influence on redox cycling and oxidative stress can also alter cellular conditions, indirectly affecting the functional landscape in which Akr1cl operates.